fda bans compounded semaglutide ban update F.D.A. officials warn of fake weight loss drugs and ban compounded versions Safe use of compounded GLP

a 92% reduction in diabetes deaths, 60% reduction in cancer deaths, 56% reduction in coronary artery disease deaths and 40% reduction in all-cause mortality was demonstrated in a retrospective matched cohort study of obese individuals undergoing bariatric surgery

Subjects receiving dulaglutide had an improvement in their blood sugar control as observed with reductions in HbA1c level (hemoglobin A1c is a measure of blood sugar control)

Enhanced Metabolic Health Beyond weight loss, retatrutide has demonstrated potential in reducing liver fat content, indicating benefits for conditions like metabolic dysfunction-associated steatotic liver disease (MASLD)

Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial